Precision Optics (POCI)
Market Price (8/24/2026): $4.43 | Market Cap: $34.5 MilSector: Health Care | Industry: Health Care Equipment
Precision Optics (POCI)
Market Price (8/24/2026): $4.43Market Cap: $34.5 MilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 64% Megatrend and thematic driversMegatrends include Autonomous Technologies, Biotechnology & Genomics, and Advanced Aviation & Space. Themes include Machine Vision, Show more. | Weak multi-year price returns2Y Excs Rtn is -50%, 3Y Excs Rtn is -101% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -4.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -16% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -5.1%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -6.6% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -18% Key risksPOCI key risks include [1] ongoing financial losses and potential funding needs, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 64% |
| Megatrend and thematic driversMegatrends include Autonomous Technologies, Biotechnology & Genomics, and Advanced Aviation & Space. Themes include Machine Vision, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -50%, 3Y Excs Rtn is -101% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -4.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -16% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -5.1%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -6.6% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -18% |
| Key risksPOCI key risks include [1] ongoing financial losses and potential funding needs, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 8/21/2026
Precision Optics (POCI) stock has gained about 10% since 4/30/2026 because of the following key factors:
1. Record-breaking Revenue Growth Driven by Core Programs.
Precision Optics reported record total revenue of $8.7 million for fiscal Q3 2026 (ended March 31, 2026), marking a 108% increase year-over-year. Production revenue also reached a record $7.6 million, growing by 131% compared to the same quarter in the previous fiscal year. This performance was significantly boosted by key programs, including $3.6 million in revenue from an aerospace customer and $2.2 million from the single-use cystoscope program, both achieving quarterly highs.
2. Achievement of Positive Adjusted EBITDA and Improved Profitability.
In a significant milestone, Precision Optics achieved positive adjusted EBITDA of $0.3 million in fiscal Q3 2026, a substantial improvement from a loss of $(1.3) million in the prior fiscal year's comparable quarter. The net loss for the quarter also narrowed considerably to $(0.1) million, down from $(2.1) million year-over-year.
Show more
Precision Optics (POCI) stock has gained about 10% since 4/30/2026 because of the following key factors:
1. Record-breaking Revenue Growth Driven by Core Programs.
Precision Optics reported record total revenue of $8.7 million for fiscal Q3 2026 (ended March 31, 2026), marking a 108% increase year-over-year. Production revenue also reached a record $7.6 million, growing by 131% compared to the same quarter in the previous fiscal year. This performance was significantly boosted by key programs, including $3.6 million in revenue from an aerospace customer and $2.2 million from the single-use cystoscope program, both achieving quarterly highs.
2. Achievement of Positive Adjusted EBITDA and Improved Profitability.
In a significant milestone, Precision Optics achieved positive adjusted EBITDA of $0.3 million in fiscal Q3 2026, a substantial improvement from a loss of $(1.3) million in the prior fiscal year's comparable quarter. The net loss for the quarter also narrowed considerably to $(0.1) million, down from $(2.1) million year-over-year.
Show more
Updated on 8/21/2026
Precision Optics (POCI) stock has gained about 10% since 4/30/2026 because of the following key factors:
1. Record-breaking Revenue Growth Driven by Core Programs.
Precision Optics reported record total revenue of $8.7 million for fiscal Q3 2026 (ended March 31, 2026), marking a 108% increase year-over-year. Production revenue also reached a record $7.6 million, growing by 131% compared to the same quarter in the previous fiscal year. This performance was significantly boosted by key programs, including $3.6 million in revenue from an aerospace customer and $2.2 million from the single-use cystoscope program, both achieving quarterly highs.
2. Achievement of Positive Adjusted EBITDA and Improved Profitability.
In a significant milestone, Precision Optics achieved positive adjusted EBITDA of $0.3 million in fiscal Q3 2026, a substantial improvement from a loss of $(1.3) million in the prior fiscal year's comparable quarter. The net loss for the quarter also narrowed considerably to $(0.1) million, down from $(2.1) million year-over-year.
3. Upward Revision of Fiscal Year 2026 Guidance.
Following the strong Q3 results, management raised its fiscal year 2026 revenue guidance to a range of $29 million to $31 million, an increase from the previous forecast of $26 million to $28 million. This revised guidance projects substantial revenue growth of 52% to 62% over fiscal year 2025. The company also tightened its adjusted EBITDA guidance to a narrower loss of $(2.5) million to $(2.7) million, improving from the prior outlook of $(2.5) million to $(3.0) million.
4. Strategic Capital Infusion and New Production Orders.
The company's balance sheet was strengthened by the successful completion of an oversubscribed $10 million public offering, which closed around March 30, 2026, bolstering cash reserves to $10.7 million as of March 31, 2026. This capital provides financial flexibility for growth initiatives and manufacturing investments. Additionally, Precision Optics secured a $3.5 million follow-on production order for a single-use ophthalmic program, with shipments anticipated to begin in fiscal Q4 2026, indicating continued strong demand and future revenue streams.
Show less
Precision Optics (POCI) stock has gained about 10% since 4/30/2026 because of the following key factors:
1. Record-breaking Revenue Growth Driven by Core Programs.
Precision Optics reported record total revenue of $8.7 million for fiscal Q3 2026 (ended March 31, 2026), marking a 108% increase year-over-year. Production revenue also reached a record $7.6 million, growing by 131% compared to the same quarter in the previous fiscal year. This performance was significantly boosted by key programs, including $3.6 million in revenue from an aerospace customer and $2.2 million from the single-use cystoscope program, both achieving quarterly highs.
2. Achievement of Positive Adjusted EBITDA and Improved Profitability.
In a significant milestone, Precision Optics achieved positive adjusted EBITDA of $0.3 million in fiscal Q3 2026, a substantial improvement from a loss of $(1.3) million in the prior fiscal year's comparable quarter. The net loss for the quarter also narrowed considerably to $(0.1) million, down from $(2.1) million year-over-year.
3. Upward Revision of Fiscal Year 2026 Guidance.
Following the strong Q3 results, management raised its fiscal year 2026 revenue guidance to a range of $29 million to $31 million, an increase from the previous forecast of $26 million to $28 million. This revised guidance projects substantial revenue growth of 52% to 62% over fiscal year 2025. The company also tightened its adjusted EBITDA guidance to a narrower loss of $(2.5) million to $(2.7) million, improving from the prior outlook of $(2.5) million to $(3.0) million.
4. Strategic Capital Infusion and New Production Orders.
The company's balance sheet was strengthened by the successful completion of an oversubscribed $10 million public offering, which closed around March 30, 2026, bolstering cash reserves to $10.7 million as of March 31, 2026. This capital provides financial flexibility for growth initiatives and manufacturing investments. Additionally, Precision Optics secured a $3.5 million follow-on production order for a single-use ophthalmic program, with shipments anticipated to begin in fiscal Q4 2026, indicating continued strong demand and future revenue streams.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 7.8% change in POCI stock from 4/30/2026 to 8/23/2026 was primarily driven by a 18.5% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302026 | 8232026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.23 | 4.56 | 7.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 24 | 29 | 18.5% |
| P/S Multiple | 1.3 | 1.2 | -8.1% |
| Shares Outstanding (Mil) | 8 | 8 | -1.0% |
| Cumulative Contribution | 7.8% |
Market Drivers
4/30/2026 to 8/23/2026| Return | Correlation | |
|---|---|---|
| POCI | 7.8% | |
| Market (SPY) | 6.5% | 23.2% |
| Sector (XLV) | 19.6% | 14.3% |
Fundamental Drivers
The -8.4% change in POCI stock from 1/31/2026 to 8/23/2026 was primarily driven by a -31.0% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 8232026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.98 | 4.56 | -8.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 22 | 29 | 34.1% |
| P/S Multiple | 1.8 | 1.2 | -31.0% |
| Shares Outstanding (Mil) | 8 | 8 | -1.0% |
| Cumulative Contribution | -8.4% |
Market Drivers
1/31/2026 to 8/23/2026| Return | Correlation | |
|---|---|---|
| POCI | -8.4% | |
| Market (SPY) | 11.0% | 6.2% |
| Sector (XLV) | 13.3% | 1.5% |
Fundamental Drivers
The -1.9% change in POCI stock from 7/31/2025 to 8/23/2026 was primarily driven by a -32.7% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 8232026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.65 | 4.56 | -1.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 18 | 29 | 64.2% |
| P/S Multiple | 1.8 | 1.2 | -32.7% |
| Shares Outstanding (Mil) | 7 | 8 | -11.3% |
| Cumulative Contribution | -1.9% |
Market Drivers
7/31/2025 to 8/23/2026| Return | Correlation | |
|---|---|---|
| POCI | -1.9% | |
| Market (SPY) | 22.2% | 9.3% |
| Sector (XLV) | 35.6% | 11.7% |
Fundamental Drivers
The -26.7% change in POCI stock from 7/31/2023 to 8/23/2026 was primarily driven by a -27.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312023 | 8232026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.22 | 4.56 | -26.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 21 | 29 | 39.0% |
| P/S Multiple | 1.7 | 1.2 | -27.1% |
| Shares Outstanding (Mil) | 6 | 8 | -27.6% |
| Cumulative Contribution | -26.7% |
Market Drivers
7/31/2023 to 8/23/2026| Return | Correlation | |
|---|---|---|
| POCI | -26.7% | |
| Market (SPY) | 73.2% | 7.1% |
| Sector (XLV) | 36.3% | 6.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| POCI Return | 0% | 13813% | 8% | -20% | -13% | 6% | 10975% |
| Peers Return | 4% | -18% | 8% | 52% | 88% | 38% | 264% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 103% |
Monthly Win Rates [3] | |||||||
| POCI Win Rate | 0% | 8% | 58% | 58% | 42% | 50% | |
| Peers Win Rate | 52% | 43% | 53% | 63% | 53% | 62% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| POCI Max Drawdown | 0% | -11% | -24% | -45% | -24% | -34% | |
| Peers Max Drawdown | -41% | -42% | -39% | -24% | -43% | -44% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: AMS, IIIV, COHR, LITE, MTSI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/21/2026 (YTD)
How Low Can It Go
| Event | POCI | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -17.6% | -18.8% |
| % Gain to Breakeven | 21.4% | 23.1% |
| Time to Breakeven | 44 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -12.0% | -7.8% |
| % Gain to Breakeven | 13.6% | 8.5% |
| Time to Breakeven | 21 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -10.1% | -9.5% |
| % Gain to Breakeven | 11.3% | 10.5% |
| Time to Breakeven | 7 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -13.2% | -6.7% |
| % Gain to Breakeven | 15.3% | 7.1% |
| Time to Breakeven | 14 days | 31 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -76.5% | -53.4% |
| % Gain to Breakeven | 325.0% | 114.4% |
| Time to Breakeven | 5112 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -21.9% | -8.6% |
| % Gain to Breakeven | 28.0% | 9.5% |
| Time to Breakeven | 21 days | 47 days |
In The Past
Precision Optics's stock fell -17.6% during the 2025 US Tariff Shock. Such a loss loss requires a 21.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | POCI | S&P 500 |
|---|---|---|
| 2008-2009 Global Financial Crisis | ||
| % Loss | -76.5% | -53.4% |
| % Gain to Breakeven | 325.0% | 114.4% |
| Time to Breakeven | 5112 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -21.9% | -8.6% |
| % Gain to Breakeven | 28.0% | 9.5% |
| Time to Breakeven | 21 days | 47 days |
In The Past
Precision Optics's stock fell -17.6% during the 2025 US Tariff Shock. Such a loss loss requires a 21.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Precision Optics (POCI)
Precision Optics Corporation (POCI) designs, develops, and manufactures specialized optical and illumination systems and related components. The company leverages its expertise to create high-precision solutions for various demanding applications, providing both complete systems and individual components.
A primary focus for Precision Optics is the medical instrumentation market. POCI offers a range of advanced medical products, including endoscopes, endocouplers, micro medical cameras, and 3D endoscopes, which are essential for minimally invasive surgical procedures. These critical products are primarily marketed to original equipment manufacturers (OEMs) and medical device companies, which then supply hospitals and physicians in the United States and the European Economic Area.
In addition to its significant presence in the medical field, Precision Optics also supplies specialized optical components and assemblies for industrial and military applications. This diversified approach allows the company to apply its core competencies in optics across multiple high-value sectors, establishing itself as a key provider of specialized optical solutions.
AI Analysis | Feedback
Analogies for Precision Optics (POCI):
- Think of them as a "Carl Zeiss for specialized miniature medical imaging and endoscopy components."
- They are like the "Intel Inside" for advanced optical systems used in medical devices and industrial equipment.
AI Analysis | Feedback
- Medical Instrumentation Products: Includes specialized optical and illumination systems such as endoscopes, endocouplers, micro medical cameras, and 3D endoscopes for minimally invasive surgical procedures.
- Industrial and Military Components: Custom-designed optical and illumination components and assemblies for industrial and military applications.
AI Analysis | Feedback
Major Customers of Precision Optics (POCI)
Based on the provided information, Precision Optics (POCI) primarily sells its products to other companies rather than individuals. While specific customer company names are not disclosed in the background description, the company's major customers can be identified by the types of companies it serves:
- Original Equipment Manufacturers (OEMs)
- Medical Device Companies (who then market products to hospitals and physicians for use in minimally invasive surgical procedures)
- Companies serving the industrial and military sectors (for components and assemblies)
AI Analysis | Feedback
null
AI Analysis | Feedback
Joseph Forkey, Chief Executive Officer, President, and Treasurer
Dr. Joseph Forkey joined Precision Optics in 2003 and has served as Chief Executive Officer, President, and Treasurer since February 8, 2011. He has over 30 years of experience in inter-disciplinary optical technology across the medical device and defense/aerospace markets, both in academic and industrial settings. Prior to his CEO role, he held positions of Executive Vice President and Chief Scientific Officer from April 2006 to February 2011, and Chief Scientist from September 2003 to April 2006. Dr. Forkey was also a member of the Board of Directors since 2006 and served as its Chairman from February 2011 to July 2014. He holds an M.A. and Ph.D. in Applied Physics/Mechanical and Aerospace Engineering from Princeton University and B.A.s in Physics and Mathematics from Cornell University.
Wayne Coll, Chief Financial Officer
Wayne Coll was appointed Chief Financial Officer effective June 12, 2023, bringing over 30 years of senior financial executive experience, primarily within medical device-based businesses. He is an experienced public company CFO with expertise in driving business models, executing strategic M&A activities, and managing access to capital markets. Before joining Precision Optics, Mr. Coll served as CFO at Flowonix Medical Incorporated (July 2021-June 2023), Micron Products, Inc. (a publicly traded medical devices and contract manufacturer, July 2019–July 2021), Keystone Dental, Inc. (October 2018-May 2019), Modern Dental Laboratory USA (October 2013-September 2018), and Pluromed (a medical device company acquired by Genzyme/Sanofi, November 2011-September 2013). He also spent nearly 20 years at National Dentex Corporation, a publicly traded dental laboratory, including 4-5 years as CFO.
Joseph Traut, Chief Operating Officer
Joseph Traut was appointed Chief Operating Officer effective October 1, 2025. He brings more than 20 years of experience leading manufacturing, operations, and technology transfer initiatives within the medical device and diagnostics industries. Most recently, Mr. Traut served as Vice President of Operations at T2 Biosystems and previously as Vice President of Technology Transfer at LumiraDx. From 2017 to 2021, he was Vice President of Manufacturing Solutions at Ximedica (now part of Veranex), where he partnered with medical technology companies for product industrialization, supply chain strengthening, and preparing organizations for commercialization and growth. Mr. Traut holds an MBA in Management of Technology from Bentley University.
Jeff DiRubio, EVP, Sales & Marketing
Jeff DiRubio serves as the Executive Vice President of Sales & Marketing.
Jonathan Everett, VP of Engineering
Jonathan Everett holds the position of Vice President of Engineering.
Dr. Joseph Forkey joined Precision Optics in 2003 and has served as Chief Executive Officer, President, and Treasurer since February 8, 2011. He has over 30 years of experience in inter-disciplinary optical technology across the medical device and defense/aerospace markets, both in academic and industrial settings. Prior to his CEO role, he held positions of Executive Vice President and Chief Scientific Officer from April 2006 to February 2011, and Chief Scientist from September 2003 to April 2006. Dr. Forkey was also a member of the Board of Directors since 2006 and served as its Chairman from February 2011 to July 2014. He holds an M.A. and Ph.D. in Applied Physics/Mechanical and Aerospace Engineering from Princeton University and B.A.s in Physics and Mathematics from Cornell University.
Wayne Coll, Chief Financial Officer
Wayne Coll was appointed Chief Financial Officer effective June 12, 2023, bringing over 30 years of senior financial executive experience, primarily within medical device-based businesses. He is an experienced public company CFO with expertise in driving business models, executing strategic M&A activities, and managing access to capital markets. Before joining Precision Optics, Mr. Coll served as CFO at Flowonix Medical Incorporated (July 2021-June 2023), Micron Products, Inc. (a publicly traded medical devices and contract manufacturer, July 2019–July 2021), Keystone Dental, Inc. (October 2018-May 2019), Modern Dental Laboratory USA (October 2013-September 2018), and Pluromed (a medical device company acquired by Genzyme/Sanofi, November 2011-September 2013). He also spent nearly 20 years at National Dentex Corporation, a publicly traded dental laboratory, including 4-5 years as CFO.
Joseph Traut, Chief Operating Officer
Joseph Traut was appointed Chief Operating Officer effective October 1, 2025. He brings more than 20 years of experience leading manufacturing, operations, and technology transfer initiatives within the medical device and diagnostics industries. Most recently, Mr. Traut served as Vice President of Operations at T2 Biosystems and previously as Vice President of Technology Transfer at LumiraDx. From 2017 to 2021, he was Vice President of Manufacturing Solutions at Ximedica (now part of Veranex), where he partnered with medical technology companies for product industrialization, supply chain strengthening, and preparing organizations for commercialization and growth. Mr. Traut holds an MBA in Management of Technology from Bentley University.
Jeff DiRubio, EVP, Sales & Marketing
Jeff DiRubio serves as the Executive Vice President of Sales & Marketing.
Jonathan Everett, VP of Engineering
Jonathan Everett holds the position of Vice President of Engineering.
AI Analysis | Feedback
The key risks to Precision Optics (POCI) primarily revolve around its financial stability, supply chain vulnerabilities, and customer concentration.
- Financial Instability and Going Concern Uncertainty: Precision Optics faces significant financial challenges, with current cash reserves insufficient to fund planned operations for at least one year, explicitly raising substantial doubt about its ability to continue as a going concern. The company has experienced severe margin compression and widening net losses despite revenue growth, primarily due to manufacturing yield issues, startup problems, and under-absorbed overhead. Furthermore, it has required waivers for minimum annual debt service coverage ratios and has failed to meet compliance for future advances, posing a substantial financing risk.
- Supply Chain Vulnerabilities: The company is highly reliant on a limited number of suppliers for critical raw materials, such as precision-grade optical glass and CMOS image sensors, with some suppliers located in China. This dependence exposes Precision Optics to potential disruptions, increased costs, and weakened competitive positioning from U.S. tariff policy changes, trade restrictions, or other supply chain interruptions.
- Customer Concentration: Precision Optics relies heavily on a small number of key customers. The loss of any significant customer could lead to a substantial decline in revenues and materially impact the company's financial performance.
AI Analysis | Feedback
null
AI Analysis | Feedback
Precision Optics Corporation, Inc. (POCI) designs, develops, manufactures, and sells specialized optical and illumination systems, with a significant focus on medical instrumentation. The addressable markets for their main products and services, primarily in the medical sector, are substantial:
Medical Cameras (including micro medical cameras and 3D endoscopes)
- The global medical camera market was valued at approximately USD 3.54 billion in 2024 and is projected to grow to USD 6.73 billion by 2033, exhibiting a Compound Annual Growth Rate (CAGR) of 7.4% during the forecast period (2026–2033). Other estimates place the global market at USD 2.7 billion in 2022, with a projection to reach USD 5.9 billion by 2032 at over 7% CAGR. Another report estimates the global market at USD 4.44 billion in 2025, projected to grow to USD 7.57 billion by 2034, with a CAGR of 6.2%.
- In North America, the medical camera market was valued at over USD 860 million in 2022.
- The European medical camera market was valued at USD 0.97 billion in 2024 and is forecasted to grow to USD 2.10 billion by 2033, at a CAGR of 8.9%.
- The endoscopy cameras segment alone accounted for the largest share of the medical camera market in 2023 and 2025, holding over 46% of the market share in 2023. High-definition (HD) cameras, which include those used in endoscopy, represented over 62% of the medical camera market's resolution segment in 2023.
Endoscopes (including endoscopes and components like Microprecision lenses and endocouplers)
- The global endoscopes market size was estimated at USD 25.18 billion in 2024 and is expected to reach USD 37.01 billion by 2032, growing at a CAGR of 4.93% from 2025-2032. Other projections indicate a global market size of USD 26.63 billion in 2025, expanding to USD 41.17 billion by 2034, at a CAGR of 4.96%.
- The U.S. endoscopes market was valued at USD 4.78 billion in 2024 and is projected to reach USD 11.22 billion by 2034, growing at a CAGR of 9% from 2025 to 2034.
- The Europe endoscopes market generated a revenue of USD 3,687.2 million in 2023 and is expected to grow at a CAGR of 9% from 2024 to 2030, reaching a projected revenue of USD 6,730.3 million by 2030.
- Within the broader endoscopy devices market, the U.S. endoscopy devices market size was estimated at USD 21.07 billion in 2023 and is projected to grow at a CAGR of 6.4% from 2024 to 2030. Similarly, the U.S. endoscopy devices market size accounted for USD 17,130 million in 2024 and is expected to exceed USD 35,970 million by 2034, growing at a CAGR of 7.7% from 2025 to 2034.
- The Europe endoscopy devices market was valued at USD 9.42 billion in 2024, is estimated to reach USD 10.05 billion in 2025, and is projected to grow at a CAGR of 6.65% from 2025 to 2033, reaching USD 16.82 billion by 2033.
- The Europe disposable endoscopes market, a sub-segment, was estimated at USD 777.2 million in 2024 and is expected to reach USD 1.21 billion by 2030, registering a CAGR of 7.73% from 2025 to 2030.
Minimally Invasive Surgical Devices
Precision Optics' products contribute to the larger minimally invasive surgical (MIS) devices market due to their use in minimally invasive surgical procedures.
- The global minimally invasive surgical instruments market size was estimated at USD 31.65 billion in 2023 and is projected to reach USD 63.04 billion by 2030, growing at a CAGR of 10.3% from 2024 to 2030. Another estimate places the global market at USD 30,798.01 million in 2025, projected to grow to USD 53,259.85 million by 2034, registering a CAGR of 7.13% from 2026 to 2034.
- North America held the dominant share in the global minimally invasive surgical instruments market in 2023. The U.S. minimally invasive surgery devices market was valued at USD 8.42 billion in 2024 and is expected to reach USD 12.14 billion by 2033, exhibiting a CAGR of 3.73%.
- The minimally invasive surgical instruments market in Europe is expected to reach a projected revenue of USD 17,009.6 million by 2030, with a CAGR of 10.5% from 2024 to 2030. The Europe minimally invasive surgery devices market recorded a value of USD 13.14 billion in 2025 and is projected to total USD 23.95 billion by 2033, registering an estimated CAGR of 7.8%.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Precision Optics (POCI)
Precision Optics (POCI) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends, primarily focusing on transitioning its robust engineering pipeline into full-scale production and expanding its presence in critical sectors.
- Transition of New Programs from Engineering to Production: A significant driver of future revenue growth for Precision Optics is the successful transition of new programs from the engineering and development phase to full production. This strategic shift is expected to substantially increase manufacturing revenue, with systems manufacturing projected to grow by at least 75% in fiscal year 2026. The company anticipates achieving record quarterly revenue run rates by the end of the fiscal year as these programs move into production.
- Expansion in the Medical Device Market with Single-Use Cystoscope Program: The single-use cystoscope program is a key growth area within the medical device market. Precision Optics anticipates continued increases in revenue from this program throughout fiscal 2026, supported by growing demand from customers and end-users, as well as the introduction of a partial second production line. Management is actively capitalizing on growth opportunities within the medical sector.
- Growth in the Defense Aerospace Market: Precision Optics is strategically expanding its footprint in the defense aerospace market. A new defense aerospace program has already begun contributing to production revenue, and the company has added sales representatives with experience in this sector. New development programs in the aerospace domain are also underway, and the aerospace program alone had a backlog exceeding $9 million as of the first quarter of fiscal year 2026.
- Recovery and Growth in the Engineering Pipeline and Product Development: The company's strong engineering pipeline is a crucial indicator of future production revenue potential. Precision Optics expects a significant recovery in its product development pipeline and has secured new large development agreements. These agreements, totaling approximately $1.4 million, are focused on advanced applications such as augmented reality systems for defense and high-resolution borescopes for jet engine inspection, indicating a healthy pipeline for future projects.
- Introduction and Adoption of the Unity Platform: The Unity platform, designed for modular endoscope development, represents a new product launch that is expanding the company's pipeline opportunities. Management has highlighted the substantial benefits of the Unity Imaging Platform to customers and expressed confidence that it will contribute to future growth. Precision Optics has also increased its research and development spending due to investments in the Unity platform.
AI Analysis | Feedback
Capital Allocation Decisions (Last 3-5 Years)
Share Issuance
- The number of shares outstanding for Precision Optics increased by 21.52% in the year leading up to March 3, 2026, reaching 7.72 million shares.
- Based on an average share price of approximately $4.50, this represents an estimated issuance of around $6.17 million in new shares during that period.
- Shares outstanding also saw an increase from 6 million as of September 30, 2024, to 8 million as of September 30, 2025.
Capital Expenditures
- Precision Optics reported annual capital expenditures of $233.5K in 2025.
- Annual capital expenditures for 2024 were $293.9K, and $50K in 2023.
- The trailing twelve months (TTM) capital expenditures as of December 31, 2025, totaled approximately $574.5K.
Peer Outperformance in Health Care Equipment
POCI has outperformed 100% of its 50 Health Care Equipment peers over 5Y. Health Care Equipment ranks 5th of 10 industries in Health Care by median 5Y return.
Share of Health Care Equipment constituents that POCI has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
46%
of 56 industry peers · -7.9% return
3Y
33%
of 55 industry peers · -25.2% return
5Y
100%
of 50 industry peers · 11300.0% return
No Health Care Equipment peer with a comparable growth profile has beaten POCI by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Health Care Equipment is POCI's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 9.5% | 82.4% | 124.2% | CAH 394% · MCK 340% · COR 184% |
| Health Care Services | 20 | 20.6% | 46.6% | 7.5% | HIMS 337% · RDNT 157% · DGX 80% |
| Managed Health Care | 8 | 29.7% | -3.0% | 0.6% | OSCR 158% · HQY 63% · ELV 14% |
| Health Care Facilities | 24 | 7.9% | -0.8% | -16.4% | THC 286% · NHC 265% · ENSG 123% |
| Health Care Equipment ← | 51 | -4.5% | -4.5% | -17.6% | POCI 11300% · UFPT 373% · GKOS 260% |
| Health Care Supplies | 12 | 33.9% | -12.1% | -26.0% | LNTH 297% · HAE 78% · MMSI 29% |
| Pharmaceuticals | 63 | 4.5% | 4.1% | -38.2% | LQDA 2499% · INDV 1253% · ETON 1190% |
| Health Care Technology | 21 | -19.9% | -53.0% | -72.5% | SPOK 115% · HSTM -1% · VEEV -23% |
| Life Sciences Tools & Services | 108 | -2.5% | -28.0% | -72.6% | SNWV 1782% · MEDP 245% · ELMD 225% |
| Biotechnology | 365 | 7.8% | -24.2% | -78.3% | BRTX 107550% · CELZ 1771% · DNTH 1543% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Precision Optics Earnings Notes | 12/16/2025 | |
| How Low Can Precision Optics Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 141.65 |
| Mkt Cap | 10.3 |
| Rev LTM | 691 |
| Op Inc LTM | 109 |
| FCF LTM | 22 |
| FCF 3Y Avg | 9 |
| CFO LTM | 66 |
| CFO 3Y Avg | 126 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 25.4% |
| Rev Chg 3Y Avg | 15.4% |
| Rev Chg Q | 34.8% |
| QoQ Delta Rev Chg LTM | 8.1% |
| Op Inc Chg LTM | 41.4% |
| Op Inc Chg 3Y Avg | 38.5% |
| Op Mgn LTM | 7.9% |
| Op Mgn 3Y Avg | 1.6% |
| QoQ Delta Op Mgn LTM | 2.3% |
| CFO/Rev LTM | 20.4% |
| CFO/Rev 3Y Avg | 10.3% |
| FCF/Rev LTM | 7.5% |
| FCF/Rev 3Y Avg | -1.9% |
Price Behavior
Price Behavior
| Market Price | $4.56 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -23.4% | |
| 50 Days | 200 Days | |
| DMA Price | $4.74 | $4.60 |
| DMA Trend | indeterminate | down |
| Distance from DMA | -3.8% | -0.9% |
| 3M | 1YR | |
| Volatility | 45.1% | 50.1% |
| Downside Capture | 150.83 | 55.46 |
| Upside Capture | 96.39 | 34.18 |
| Correlation (SPY) | 21.3% | 10.2% |
POCI Betas & Captures as of 7/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.71 | 0.79 | 0.97 | 0.28 | 0.38 | 0.23 |
| Up Beta | 0.69 | -0.05 | 0.56 | 0.24 | 0.43 | 0.39 |
| Down Beta | 3.10 | -0.83 | 0.44 | 0.19 | 0.13 | -0.01 |
| Up Capture | 179% | 88% | 121% | 8% | 25% | 3% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 7 | 16 | 28 | 54 | 106 | 317 |
| Down Capture | 414% | 214% | 136% | 59% | 66% | 59% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 13 | 25 | 33 | 70 | 137 | 370 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with POCI | |
|---|---|---|---|---|
| POCI | -2.8% | 50.4% | 0.10 | - |
| Sector ETF (XLV) | 28.8% | 16.0% | 1.39 | 12.5% |
| Equity (SPY) | 21.1% | 12.9% | 1.22 | 10.6% |
| Gold (GLD) | 37.5% | 28.8% | 1.10 | 1.0% |
| Commodities (DBC) | 43.2% | 20.2% | 1.66 | -5.8% |
| Real Estate (VNQ) | 12.9% | 13.8% | 0.64 | 7.4% |
| Bitcoin (BTCUSD) | -31.6% | 44.1% | -0.73 | -3.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with POCI | |
|---|---|---|---|---|
| POCI | 1.5% | 50.1% | 0.21 | - |
| Sector ETF (XLV) | 7.1% | 15.1% | 0.28 | 8.6% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 10.5% |
| Gold (GLD) | 20.6% | 18.6% | 0.90 | 0.3% |
| Commodities (DBC) | 10.4% | 19.6% | 0.41 | -2.4% |
| Real Estate (VNQ) | 2.3% | 18.9% | 0.02 | 6.6% |
| Bitcoin (BTCUSD) | 10.4% | 52.8% | 0.38 | 4.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with POCI | |
|---|---|---|---|---|
| POCI | 0.7% | 50.1% | 0.21 | - |
| Sector ETF (XLV) | 10.7% | 16.7% | 0.52 | 8.6% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 10.5% |
| Gold (GLD) | 12.7% | 16.2% | 0.64 | 0.3% |
| Commodities (DBC) | 8.0% | 18.0% | 0.36 | -2.4% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.20 | 6.6% |
| Bitcoin (BTCUSD) | 63.1% | 66.1% | 1.03 | 4.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/1/2024 | -3.7% | -13.3% | -27.4% |
| 8/14/2024 | -9.2% | -11.8% | -10.1% |
| 10/20/2022 | 0.0% | 0.0% | 14,475.0% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 1 |
| # Negative | 2 | 2 | 2 |
| Median Positive | 0.0% | 0.0% | 14,475.0% |
| Median Negative | -6.5% | -12.6% | -18.7% |
| Max Positive | 0.0% | 0.0% | 14,475.0% |
| Max Negative | -9.2% | -13.3% | -27.4% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/1/2024 | -3.7% | -13.3% | -27.4% |
| 8/14/2024 | -9.2% | -11.8% | -10.1% |
| 10/20/2022 | 0.0% | 0.0% | 14,475.0% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 1 |
| # Negative | 2 | 2 | 2 |
| Median Positive | 0.0% | 0.0% | 14,475.0% |
| Median Negative | -6.5% | -12.6% | -18.7% |
| Max Positive | 0.0% | 0.0% | 14,475.0% |
| Max Negative | -9.2% | -13.3% | -27.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 02/17/2026 | 10-Q |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 09/29/2025 | 10-K |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 02/13/2025 | 10-Q |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 09/30/2024 | 10-K |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 02/14/2024 | 10-Q |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 09/28/2023 | 10-K |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 02/14/2023 | 10-Q |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 09/27/2022 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 02/17/2026 | 10-Q |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 09/29/2025 | 10-K |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 02/13/2025 | 10-Q |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 09/30/2024 | 10-K |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 02/14/2024 | 10-Q |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 09/28/2023 | 10-K |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 02/14/2023 | 10-Q |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 09/27/2022 | 10-K |
| 03/31/2022 | 05/16/2022 | 10-Q |
| 12/31/2021 | 02/14/2022 | 10-Q |
| 09/30/2021 | 11/15/2021 | 10-Q |
| 06/30/2021 | 09/28/2021 | 10-K |
| 03/31/2021 | 05/13/2021 | 10-Q |
| 12/31/2020 | 02/16/2021 | 10-Q |
| 09/30/2020 | 11/12/2020 | 10-Q |
| 06/30/2020 | 09/24/2020 | 10-K |
| 03/31/2020 | 05/14/2020 | 10-Q |
| 12/31/2019 | 02/13/2020 | 10-Q |
| 09/30/2019 | 11/14/2019 | 10-Q |
| 06/30/2019 | 09/26/2019 | 10-K |
Insider Activity
Updated 8/13/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Coll, Wayne M | Chief Financial Officer | Direct | Buy | 4012026 | 3.60 | 20,833 | 74,999 | 126,860 | Form |
| 2 | Forkey, Joseph Norman | Chief Executive Officer | Direct | Buy | 4012026 | 3.60 | 1,388 | 4,997 | 518,252 | Form |
| 3 | Traut, Joseph | Chief Operating Officer | Direct | Buy | 4012026 | 3.60 | 41,666 | 149,998 | 149,998 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Coll, Wayne M | Chief Financial Officer | Direct | Buy | 4012026 | 3.60 | 20,833 | 74,999 | 126,860 | Form |
| 2 | Forkey, Joseph Norman | Chief Executive Officer | Direct | Buy | 4012026 | 3.60 | 1,388 | 4,997 | 518,252 | Form |
| 3 | Traut, Joseph | Chief Operating Officer | Direct | Buy | 4012026 | 3.60 | 41,666 | 149,998 | 149,998 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 8/23/2026